Last quarter (Q4 2023), Corbus Pharmaceuticals's total revenue was $―, a decrease of ― from the same quarter last year. In Q4, Corbus Pharmaceuticals's net income was $-8.02M. See Corbus Pharmaceuticals’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 23	Dec 22	Dec 21	Dec 20	Dec 19
Total Revenue	-	-	-	$ 881.71K	$ 3.94M	$ 36.14M
Cost of Revenue	-	-	-	-	-	-
Gross Profit	-	-	-	$ 881.71K	-	-
Operating Expense	$ 45.08M	$ 45.08M	$ -34.84M	$ 56.87M	$ 126.75M	$ 113.25M
Operating Income	$ -45.08M	$ -45.08M	$ -34.84M	$ -55.99M	$ -122.81M	$ -77.10M
Net Non Operating Interest Income Expense	$ -1.31M	$ -2.92M	$ -2.13M	$ -1.83M	$ -1.03M	$ 1.23M
Other Income Expense	$ -3.51M	$ -3.51M	$ 5.38M	$ -12.50M	$ 12.57M	$ 4.42M
Pretax Income	$ -44.48M	$ -44.48M	$ -42.35M	$ -45.70M	$ -111.27M	$ -71.45M
Tax Provision	-	-	-	-	-	-
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	$ -44.53M	$ -44.60M	$ -42.35M	$ -45.70M	$ -111.27M	$ -71.45M
Basic EPS	$ -10.37	$ -10.31	$ -10.15	$ -11.10	$ -1.42	$ -1.12
Diluted EPS	$ -10.31	$ -10.31	$ -10.15	$ -11.10	$ -1.42	$ -1.12
Basic Average Shares	$ 17.31M	$ 4.33M	$ 4.17M	$ 4.10M	$ 78.13M	$ 63.90M
Diluted Average Shares	$ 17.31M	$ 4.33M	$ 4.17M	$ 4.10M	$ 78.13M	$ 63.90M
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	-
Total Expenses	$ 45.08M	$ 45.08M	$ 39.84M	$ 56.87M	$ 126.75M	$ 113.25M
Net Income From Continuing And Discontinued Operation	$ -44.60M	$ -44.60M	$ -42.35M	$ -45.70M	$ -111.27M	$ -71.45M
Normalized Income	$ -21.17M	$ -35.14M	$ -28.50M	-	$ -110.57M	$ -71.30M
Interest Expense	-	-	-	-	-	-
EBIT	$ -43.17M	$ -41.55M	$ -40.28M	$ -43.87M	$ -122.81M	$ -77.10M
EBITDA	$ -34.33M	$ -40.09M	$ -37.92M	$ -40.83M	$ -121.12M	$ -75.87M

Currency in USD

Corbus Pharmaceuticals Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing